ArQule, Inc. (NASDAQ:ARQL) CEO Paolo Pucci bought 16,397 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were acquired at an average price of $1.15 per share, with a total value of $18,856.55. Following the purchase, the chief executive officer now owns 403,093 shares of the company’s stock, valued at $463,556.95. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Paolo Pucci also recently made the following trade(s):

  • On Tuesday, September 5th, Paolo Pucci bought 19,156 shares of ArQule stock. The shares were acquired at an average price of $1.14 per share, with a total value of $21,837.84.
  • On Tuesday, August 29th, Paolo Pucci bought 300 shares of ArQule stock. The shares were acquired at an average price of $1.05 per share, with a total value of $315.00.
  • On Monday, August 28th, Paolo Pucci acquired 2,970 shares of ArQule stock. The stock was purchased at an average price of $1.05 per share, with a total value of $3,118.50.
  • On Friday, August 25th, Paolo Pucci acquired 9,492 shares of ArQule stock. The stock was purchased at an average price of $1.05 per share, with a total value of $9,966.60.

Shares of ArQule, Inc. (ARQL) traded up 0.87% during midday trading on Thursday, reaching $1.16. The company’s stock had a trading volume of 132,306 shares. The firm’s market capitalization is $82.56 million. The company’s 50-day moving average price is $1.11 and its 200 day moving average price is $1.14. ArQule, Inc. has a 1-year low of $0.92 and a 1-year high of $1.82.

ArQule (NASDAQ:ARQL) last issued its quarterly earnings data on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. ArQule had a negative return on equity of 135.68% and a negative net margin of 482.44%. During the same quarter last year, the firm posted ($0.07) earnings per share. On average, equities research analysts forecast that ArQule, Inc. will post ($0.43) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Insider Buying: ArQule, Inc. (ARQL) CEO Acquires 16,397 Shares of Stock” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/07/insider-buying-arqule-inc-arql-ceo-acquires-16397-shares-of-stock.html.

An institutional investor recently raised its position in ArQule stock. Northern Trust Corp grew its position in shares of ArQule, Inc. (NASDAQ:ARQL) by 0.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 154,513 shares of the biotechnology company’s stock after buying an additional 1,385 shares during the period. Northern Trust Corp owned about 0.22% of ArQule worth $192,000 as of its most recent SEC filing. 60.95% of the stock is owned by institutional investors.

A number of equities research analysts have weighed in on ARQL shares. Zacks Investment Research upgraded ArQule from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Thursday, August 10th. ValuEngine cut ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.